<?xml version='1.0' encoding='utf-8'?>
<document id="8807660"><sentence text="A fluvoxamine-caffeine interaction study."><entity charOffset="2-13" id="DDI-PubMed.8807660.s1.e0" text="fluvoxamine" /><entity charOffset="14-22" id="DDI-PubMed.8807660.s1.e1" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.8807660.s1.e0" e2="DDI-PubMed.8807660.s1.e0" /><pair ddi="false" e1="DDI-PubMed.8807660.s1.e0" e2="DDI-PubMed.8807660.s1.e1" /></sentence><sentence text="The selective serotonin reuptake inhibitor fluvoxamine is a very potent inhibitor of the liver enzyme CYP1A2, which is the major P450 catalysing the biotransformation of caffeine"><entity charOffset="14-23" id="DDI-PubMed.8807660.s2.e0" text="serotonin" /><entity charOffset="43-54" id="DDI-PubMed.8807660.s2.e1" text="fluvoxamine" /><entity charOffset="170-178" id="DDI-PubMed.8807660.s2.e2" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.8807660.s2.e0" e2="DDI-PubMed.8807660.s2.e0" /><pair ddi="false" e1="DDI-PubMed.8807660.s2.e0" e2="DDI-PubMed.8807660.s2.e1" /><pair ddi="false" e1="DDI-PubMed.8807660.s2.e0" e2="DDI-PubMed.8807660.s2.e2" /><pair ddi="false" e1="DDI-PubMed.8807660.s2.e1" e2="DDI-PubMed.8807660.s2.e1" /><pair ddi="false" e1="DDI-PubMed.8807660.s2.e1" e2="DDI-PubMed.8807660.s2.e2" /></sentence><sentence text=" Thus, a pharmacokinetic study was undertaken with the purpose of documenting a drug-drug interaction between fluvoxamine and caffeine"><entity charOffset="110-121" id="DDI-PubMed.8807660.s3.e0" text="fluvoxamine" /><entity charOffset="126-134" id="DDI-PubMed.8807660.s3.e1" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.8807660.s3.e0" e2="DDI-PubMed.8807660.s3.e0" /><pair ddi="false" e1="DDI-PubMed.8807660.s3.e0" e2="DDI-PubMed.8807660.s3.e1" /></sentence><sentence text=" The study was carried out as a randomized, in vivo, cross-over study including eight healthy volunteers" /><sentence text=" In Period A of the study, each subject took 200 mg caffeine orally, and in Period B, the subjects took fluvoxamine 50 mg per day for 4 days and 100 mg per day for 8 days"><entity charOffset="52-60" id="DDI-PubMed.8807660.s5.e0" text="caffeine" /><entity charOffset="104-115" id="DDI-PubMed.8807660.s5.e1" text="fluvoxamine" /><pair ddi="false" e1="DDI-PubMed.8807660.s5.e0" e2="DDI-PubMed.8807660.s5.e0" /><pair ddi="false" e1="DDI-PubMed.8807660.s5.e0" e2="DDI-PubMed.8807660.s5.e1" /></sentence><sentence text=" On day 8 in Period B, the subjects again ingested 200 mg caffeine"><entity charOffset="58-66" id="DDI-PubMed.8807660.s6.e0" text="caffeine" /></sentence><sentence text=" After caffeine intake, blood and urine were sampled at regular intervals"><entity charOffset="7-15" id="DDI-PubMed.8807660.s7.e0" text="caffeine" /></sentence><sentence text=" Caffeine and its three primary demethylated metabolites, paraxanthine, theobromine and theophylline in plasma and the same four compounds plus 11 more metabolites in urine were assayed by HPLC"><entity charOffset="1-9" id="DDI-PubMed.8807660.s8.e0" text="Caffeine" /><entity charOffset="58-70" id="DDI-PubMed.8807660.s8.e1" text="paraxanthine" /><entity charOffset="72-83" id="DDI-PubMed.8807660.s8.e2" text="theobromine" /><entity charOffset="88-100" id="DDI-PubMed.8807660.s8.e3" text="theophylline" /><pair ddi="false" e1="DDI-PubMed.8807660.s8.e0" e2="DDI-PubMed.8807660.s8.e0" /><pair ddi="false" e1="DDI-PubMed.8807660.s8.e0" e2="DDI-PubMed.8807660.s8.e1" /><pair ddi="false" e1="DDI-PubMed.8807660.s8.e0" e2="DDI-PubMed.8807660.s8.e2" /><pair ddi="false" e1="DDI-PubMed.8807660.s8.e0" e2="DDI-PubMed.8807660.s8.e3" /><pair ddi="false" e1="DDI-PubMed.8807660.s8.e1" e2="DDI-PubMed.8807660.s8.e1" /><pair ddi="false" e1="DDI-PubMed.8807660.s8.e1" e2="DDI-PubMed.8807660.s8.e2" /><pair ddi="false" e1="DDI-PubMed.8807660.s8.e1" e2="DDI-PubMed.8807660.s8.e3" /><pair ddi="false" e1="DDI-PubMed.8807660.s8.e2" e2="DDI-PubMed.8807660.s8.e2" /><pair ddi="false" e1="DDI-PubMed.8807660.s8.e2" e2="DDI-PubMed.8807660.s8.e3" /></sentence><sentence text=" During fluvoxamine, the median of the total clearance of caffeine decreased from 107 ml min-1 to 21 ml min-1 and the half-life increased from 5 to 31 h"><entity charOffset="8-19" id="DDI-PubMed.8807660.s9.e0" text="fluvoxamine" /><entity charOffset="58-66" id="DDI-PubMed.8807660.s9.e1" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.8807660.s9.e0" e2="DDI-PubMed.8807660.s9.e0" /><pair ddi="false" e1="DDI-PubMed.8807660.s9.e0" e2="DDI-PubMed.8807660.s9.e1" /></sentence><sentence text=" The N3-demethylation clearance of caffeine to paraxanthine decreased from 46 to 9 ml min-1; the N1- and N7-demethylation clearances decreased from 21 to 9 ml min-1 and from 14 to 6 ml min-1, respectively"><entity charOffset="35-43" id="DDI-PubMed.8807660.s10.e0" text="caffeine" /><entity charOffset="47-59" id="DDI-PubMed.8807660.s10.e1" text="paraxanthine" /><pair ddi="false" e1="DDI-PubMed.8807660.s10.e0" e2="DDI-PubMed.8807660.s10.e0" /><pair ddi="false" e1="DDI-PubMed.8807660.s10.e0" e2="DDI-PubMed.8807660.s10.e1" /></sentence><sentence text=" The results confirm that CYP1A2 is the main enzyme catalysing the biotransformation of caffeine, in particular the N3-demethylation and partly the N1- and N7-demethylation"><entity charOffset="88-96" id="DDI-PubMed.8807660.s11.e0" text="caffeine" /></sentence><sentence text=" The results indicate that intake of caffeine during fluvoxamine treatment may lead to caffeine intoxication"><entity charOffset="37-45" id="DDI-PubMed.8807660.s12.e0" text="caffeine" /><entity charOffset="53-64" id="DDI-PubMed.8807660.s12.e1" text="fluvoxamine" /><entity charOffset="87-95" id="DDI-PubMed.8807660.s12.e2" text="caffeine" /><pair ddi="false" e1="DDI-PubMed.8807660.s12.e0" e2="DDI-PubMed.8807660.s12.e0" /><pair ddi="false" e1="DDI-PubMed.8807660.s12.e0" e2="DDI-PubMed.8807660.s12.e1" /><pair ddi="false" e1="DDI-PubMed.8807660.s12.e0" e2="DDI-PubMed.8807660.s12.e2" /><pair ddi="false" e1="DDI-PubMed.8807660.s12.e1" e2="DDI-PubMed.8807660.s12.e1" /><pair ddi="false" e1="DDI-PubMed.8807660.s12.e1" e2="DDI-PubMed.8807660.s12.e2" /></sentence><sentence text=" Finally, our study provides additional evidence that fluvoxamine can be used to probe CYP1A2 in drug metabolism"><entity charOffset="54-65" id="DDI-PubMed.8807660.s13.e0" text="fluvoxamine" /></sentence><sentence text="" /></document>